Zogenix nets $60.7m for Zohydro and Sumavel plus debt repayment
This article was originally published in Scrip
Executive Summary
Zogenix, a pharmaceutical company focused on central nervous system disorders and pain, priced 32.5 million shares of common stock plus warrants at $2 per share on 24 July for net proceeds of $60.7 million to finance operations related to the approval and commercialization of the oral extended-release hydrocodone therapy Zohydro, among other expenses.